Idorsia (formerly Actelion) is a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. It targets a number of different diseases, such as Fabry disease, insomnia, resistant hypertension, cerebral vasospasm, epilepsy, nasal polyposis, systemic lupus erythematosus, and others. The company focuses on multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.